Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-10
1999-02-02
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514561, 546224, A61K 31445
Patent
active
058665919
ABSTRACT:
-oxopropyl)phenylamino!-1-piperidine!propanoic acid, methyl ester, generally referred to as remifentanil, are disclosed. In particular, stabilized lyophilized solid composition are disclosed comprising certain acids, most preferably comprising glycine.
REFERENCES:
patent: 5019583 (1991-05-01), Feldman et al.
patent: 5039804 (1991-08-01), Feldman et al.
patent: 5126455 (1992-06-01), Feldman et al.
patent: 5268368 (1993-12-01), Palepu
patent: 5466700 (1995-11-01), Batenhorst et al.
Akers et al., Glycine Crystallization During Freezing: The Effects of Salt Form, pH, and Ionic Strength, Pharmacuetical Research, vol. 12, No. 10, pp. 1457-1461 (1995).
Feldman et al., Design, Synthesis, and Pharmacological Evaluation of Ultrashort--to Long-Acting Opioid Analgetics, Journal of Medicinal Chemistry, 1991, vol. 34, No. 7, pp. 2202-2208.
James et al., Opioid Receptor Activity of GI 87084B, a Novel Ultra-Short Acting Analgesic, in Isolated Tissues, Journal of Pharmacology and Experimental Therapeutics , 1991 vol. 259, No. 2, pp. 712-718.
Lutz et al., A Pharmacodynamic Model to Investigate the Structure-Activity Profile of a Series of Novel Opioid Analgesics, Journal of Pharmacology and Experimental Therapeutics, 1994, vol. 271, No. 2, pp. 795-803.
Remifentanil Hydrochloride, Drugs of the Future 1994, 19(12)pp. 1088-1092.
Remifentanil Hydrochloride Ultiva, Drugs of the Future 1995, 20(12) pp. 1296-1298.
Amin et al., Naloxone Reversal of Depressed Ventilatory Response to Hypoxia During Continuous Infusion of Remifentanil, Anesthesiology, V.79, No. 3A, Sep. 1993, A1203.
Amin et al., Naloxone-Induced and Spontaneous reversal of Depressed Ventilatory Responses to Hypoxia during and after Continuous Infusion of Remifentanil or Alfentanil, Journal of Phamacology and Experimental Therapeutics, vol. 274, No. 1, 1995, pp. 34-39.
Zadeii et al., Stability of Ethiofos (NSC-29691) in Aqueous Solution and Solid Phase Formulation Pharmaceutical Research, vol. 8, No. 10, 1991, pp. S172, PDD7184./
Korey et al., Effects of Excipients on the Crystallization of Pharmaceutical Compounds During Lyophilization, Journal of Parenteral Science & Technology, vol. 43, No. 2, Mar.-Apr. 1, 1989.
Bashir et al., Evaluation of Freeze-Dried Products for Injection, Bulletin of Parenteral Association, vol. 27, No. 2, Mar.-Apr. 1973, pp. 68-83.
Wang et al., Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers, Parenteral Science and Technology, vol. 42, No. 2S, 1988 Supplement, Tech. Report No. 10.
Nail et al., Freeze Drying: Principles and Practice, Pharmaceutical Dosage Forms-Parenteral Medications, 2nd Edition, vol. 2, 1993, pp. 163-233.
"Tablet Formulation and Design", Pharmaceutical Dosage Forms-Tablets, 2nd Edition, vol. 1, 1989, p. 105.
Ash et al., Handbook of Pharmaceutical Additives, 1995, p. 524.
Gatlin Larry Alan
Heiman Shirley Ann
Lewis Janet Sue
Brink Robert H.
Cook Rebecca
Glaxo Wellcome Inc.
Makujina Shah R.
LandOfFree
Stable formulations of remifentanil does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable formulations of remifentanil, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable formulations of remifentanil will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117810